The uptake of continuous manufacturing, a faster and more flexible production process, has lagged in the risk-averse pharma and biotech industries.
Still, a number of the larger companies have dipped their toes in the water, including GlaxoSmithKline, Vertex, Johnson & Johnson and Eli Lilly. In addition to its collaboration with CPI, GlaxoSmithKline is working with the Center for Structured Organic Particulate Systems at Rutgers University to expand its knowledge of continuous manufacturing.
{iframe}https://www.biopharmadive.com/news/gsk-astrazeneca-continuous-manufacturing-cpi/552557/{/iframe}